-
Publication Venue For
-
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies..
40:621-631.
2019
-
Fourth universal definition of myocardial infarction (2018)..
40:237-269.
2019
-
Risk stratification for stroke in atrial fibrillation: a critique.
2018
-
Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF..
39:4255-4256.
2018
-
Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
2018
-
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials..
39:3810-3820.
2018
-
Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry..
39:3701-3711.
2018
-
The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial..
39:3464-3471.
2018
-
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation..
39:2942-2955.
2018
-
Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe..
39:2932-2941.
2018
-
Transitioning fromusual care to biomarkerbased personalized and precisionmedicine in heart failure: Call for action.
39:2793-2798.
2018
-
Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?.
39:2956-2958.
2018
-
Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke..
39:2376-2386.
2018
-
Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome..
39:2460-2468.
2018
-
The incidence and prognostic implications of worsening right ventricular function after surgical or transcatheter aortic valve replacement: insights from PARTNER IIA..
39:2659-2667.
2018
-
Application of net reclassification index to non-nested and point-based risk prediction models: a review.
2018
-
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials..
39:2208-2216.
2018
-
Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document..
39:2192-2207.
2018
-
Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?.
39:1438-1441.
2018
-
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score..
39:477-485.
2018
-
Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?.
39:450-452.
2018
-
Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?.
39:461-463.
2018
-
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy..
39:193-200.
2018
-
Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation.
2017
-
Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials..
38:3502-3510.
2017
-
Staging classification of aortic stenosis based on the extent of cardiac damage..
38:3351-3358.
2017
-
Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke..
38:2827-2835.
2017
-
Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial..
38:2813-2822.
2017
-
Global position paper on cardiovascular regenerative medicine..
38:2532-2546.
2017
-
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)..
38:2364-2373.
2017
-
Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough?.
38:2440-2443.
2017
-
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary..
38:2137-2149.
2017
-
HIV infection, ACS, PCI and high platelet reactivity: Ingredients for a perfect thrombotic storm.
38:1687-1689.
2017
-
Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials..
38:1656-1663.
2017
-
Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges..
38:1805-1814.
2017
-
Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial..
38:648-660.
2017
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1..
38:852-859.
2017
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2..
38:860-868.
2017
-
Left atrial appendage occlusion: rationale, evidence, devices, and patient selection..
38:869-876.
2017
-
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial..
38:804-810.
2017
-
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative.
2017
-
A view from the side-line..
37:3488-3489.
2016
-
Anticoagulation in coronary intervention..
37:3376-3385.
2016
-
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial..
37:3576-3584.
2016
-
Troponins in equipoise.
37:3333-3334.
2016
-
Genetic cardiovascular risk prediction: are we already there?.
37:3279-3281.
2016
-
Risk stratification in non-ST elevation acute coronary syndromes: searching for the right formula.
37:3111-3113.
2016
-
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial..
37:2869-2878.
2016
-
Highly sensitive troponin and coronary computed tomography angiography in the evaluation of suspected acute coronary syndrome in the emergency department.
37:2397-2405.
2016
-
Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction..
37:2276-2286.
2016
-
Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease..
37:1993-2001.
2016
-
Finerenone in heart failure: walking a fine line..
37:2115-2117.
2016
-
Outcomes of transfemoral transcatheter aortic valve implantation at hospitals with and without on-site cardiac surgery department: insights from the prospective German aortic valve replacement quality assurance registry (AQUA) in 17 919 patients..
37:2240-2248.
2016
-
Genetic variants and disease: correlate or cause?.
37:1476-1478.
2016
-
Left atrial appendage to great cardiac vein fistula complicating watchman left atrial appendage closure..
37:1602.
2016
-
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation..
37:1582-1590.
2016
-
Assessing generalizability of trial results in general practice..
37:1154-1157.
2016
-
Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma..
37:1143-1144.
2016
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
2016
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
2016
-
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome..
37:412-422.
2016
-
CardioPulse: Platelet inhibitors and their differences..
37:323-326.
2016
-
Lessons learned and a look to the future: The chronic ischemic heart disease (CICD) pilot registry.
37:161-163.
2016
-
The ORBIT bleeding score: A simple bedside score to assess bleeding risk in atrial fibrillation.
36:3258-3264.
2015
-
Atrial fibrillation in heart failure: what should we do?.
36:3250-3257.
2015
-
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial..
36:3268-3275.
2015
-
Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study..
36:3359-3367.
2015
-
Nox4 NADPH oxidase: emerging from the veil of darkness..
36:3457-3459.
2015
-
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation..
36:3258-3264.
2015
-
Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction..
36:2733-2741.
2015
-
Augmenting outcomes in patients with advanced heart failure..
36:2276-2278.
2015
-
Cardiovascular precision medicine: hope or hype?.
36:1842-1843.
2015
-
Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium..
36:1851-1877.
2015
-
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes..
36:1901-1912.
2015
-
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention..
36:1762-1771.
2015
-
Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS)..
36:1689-1696.
2015
-
The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring..
36:1640-1642.
2015
-
Should patients on vitamin K antagonists be treated differently?.
36:1431-1433.
2015
-
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial..
36:1264-1272.
2015
-
Management of cardiogenic shock..
36:1223-1230.
2015
-
Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers..
36:847-855.
2015
-
The end of an electrocardiographic dogma: a prominent R wave in V1 is caused by a lateral not posterior myocardial infarction-new evidence based on contrast-enhanced cardiac magnetic resonance-electrocardiogram correlations..
36:959-964.
2015
-
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension..
36:566-575.
2015
-
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program..
36:669-675.
2015
-
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial..
36:385-92a.
2015
-
Can copeptin emerge from the growing shadow of the troponins?.
36:333-336.
2015
-
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
36:288-296.
2015
-
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial..
36:288-296.
2015
-
LCZ696: too good to be true?.
36:410-412.
2015
-
Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes..
36:449-456.
2015
-
The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling..
36:440-448.
2015
-
Current worldwide nuclear cardiology practices andradiationexposure: Results from the 65country IAEA nuclear cardiology protocols cross-sectional study (INCAPS).
36:1689-1696.
2015
-
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial..
36:219-227.
2015
-
Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention..
35:3323-3325.
2014
-
Chest pain in patients with heart failure: why history may matter..
35:3408-3409.
2014
-
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial..
35:3377-3385.
2014
-
Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure..
35:3434-3441.
2014
-
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry..
35:2864-2872.
2014
-
Ameliorating reperfusion injury in STEMI: dead or alive?.
35:2504-2506.
2014
-
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial..
35:2516-2523.
2014
-
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial..
35:2524-2529.
2014
-
Prognostic implication of the new peri-PCI (type 4a) myocardial infarction definition according to the third universal definition of myocardial infarction in patients with NSTE ACS.
35:138-138.
2014
-
Diagnosis of pheochromocytoma on physical examination..
35:1705.
2014
-
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial..
35:1864-1872.
2014
-
Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?.
35:1834-1835.
2014
-
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
35:1873-1880.
2014
-
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial..
35:1873-1880.
2014
-
Statistical considerations in economic evaluations: a guide for cardiologists..
35:1652-1656.
2014
-
Early management of atrial fibrillation to prevent cardiovascular complications..
35:1448-1456.
2014
-
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis..
35:1559-1567.
2014
-
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial..
35:1541-1550.
2014
-
The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions..
35:1526-1532.
2014
-
Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial..
35:1041-1050.
2014
-
The enigmatic search for optimal DAPT duration..
35:951-954.
2014
-
Large simple trials: really, it can't be that simple!.
35:549-551.
2014
-
Large streamlined trials in cardiovascular disease..
35:544-548.
2014
-
The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology..
35:665-672.
2014
-
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis..
35:455-469.
2014
-
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial..
35:224-232.
2014
-
Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT..
35:106-115.
2014
-
Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke..
35:250-256.
2014
-
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
35:242-249.
2014
-
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF..
35:242-249.
2014
-
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
35:233-241.
2014
-
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial..
35:233-241.
2014
-
Natriuretic peptide-guided heart failure management..
35:16-24.
2014
-
Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
34:3342-3352.
2013
-
Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction.
34:3171-3172.
2013
-
Physical activity in patients with stable coronary heart disease: an international perspective..
34:3286-3293.
2013
-
RELAX-AHF: consistency across subgroups and new hypotheses generated.
34:3100-3101.
2013
-
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial..
34:3117-3127.
2013
-
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF..
34:3128-3136.
2013
-
Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial..
34:2271-2280.
2013
-
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?.
34:2429-2431.
2013
-
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial..
34:2464-2471.
2013
-
Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials.
34:787-787.
2013
-
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis..
34:1670-1680.
2013
-
Biomarkers in atrial fibrillation: a clinical review..
34:1475-1480.
2013
-
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis..
34:1204-1214.
2013
-
Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint..
34:903-908.
2013
-
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review..
34:894-902d.
2013
-
Spousal depression, anxiety, and suicide after myocardial infarction..
34:649-656.
2013
-
How country-specific should a country-specific cost-effectiveness analysis be?.
34:166-167.
2013
-
Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy.
34:39-47.
2013
-
Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy.
34:48-56.
2013
-
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial..
33:2821-2830.
2012
-
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice..
33:2782-2795.
2012
-
Clinical update: Remaining challenges and opportunities for improvement in percutaneous transradial coronary procedures..
33:2521-2526.
2012
-
Road mapping ATLAS ACS 2: are we there yet?.
33:2510-2512.
2012
-
Third universal definition of myocardial infarction..
33:2551-2567.
2012
-
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document..
33:2403-2418.
2012
-
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study..
33:2151-2162.
2012
-
Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea..
33:2197-2205.
2012
-
Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section..
33:2265-2271.
2012
-
Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure..
33:2317-2324.
2012
-
The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction..
33:2044-2053.
2012
-
Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community..
33:1734-1741.
2012
-
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis..
33:1750-1757.
2012
-
Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome..
33:1095-1104.
2012
-
Toward a therapeutic window for antiplatelet therapy in the elderly..
33:1187-1189.
2012
-
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial..
32:2933-2944.
2011
-
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes..
32:2945-2953.
2011
-
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)..
32:2999-3054.
2011
-
Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study..
32:3098-3106.
2011
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial..
32:2781-2789.
2011
-
Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial..
32:2563-2572.
2011
-
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment..
32:2387-2394.
2011
-
Contributions of peak expiratory flow to assessment of acute decompensated heart failure: insights from ASCEND-HF.
32:964-964.
2011
-
Gender paradox: higher incidence but lower one-year mortality with bleeding among women compared with men following fibrinolysis for acute ST-elevation myocardial infarction.
32:166-166.
2011
-
The independent prognostic value of hyponatremia in a cohort of heart failure patients: analysis from the Duke databank for cardiovascular disease.
32:134-134.
2011
-
Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the APEX-AMI trial.
32:872-872.
2011
-
Who should have a routine early invasive approach after fibrinolytic therapy?.
32:1961-1963.
2011
-
Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology..
32:1673-1686.
2011
-
Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT..
32:1622-1630.
2011
-
The future of clinical trials in secondary prevention after acute coronary syndromes..
32:1583-1589.
2011
-
Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients..
32:574-580.
2011
-
Fractal analysis of retinal microvasculature and coronary heart disease mortality..
32:422-429.
2011
-
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium..
32:205-217.
2011
-
Bleeding in acute coronary syndromes and percutaneous coronary interventions: Position paper by the Working Group on Thrombosis of the European Society of Cardiology.
32:1854-1864.
2011
-
RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
32:2541-2554.
2011
-
Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis..
31:2156-2169.
2010
-
Age-dependent values of N-terminal pro-B-type natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care..
31:1881-1889.
2010
-
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial..
31:1708-1716.
2010
-
The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences..
31:1188-1196.
2010
-
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria..
31:806-814.
2010
-
Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes..
31:958-966.
2010
-
Towards a new order in cardiovascular medicine: re-engineering through global collaboration..
31:911-917.
2010
-
The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative..
31:552-560.
2010
-
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications..
31:227-235.
2010
-
Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: An international perspective.
31:1328-1336.
2010
-
Factors related to heart rupture in acute coronary syndromes in the global registry of acute coronary events.
31:1449-1456.
2010
-
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? the global registry of acute coronary events.
31:667-675.
2010
-
Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
31:1181-1187.
2010
-
Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: Insights from the APEX-AMI trial.
31:1701-1707.
2010
-
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial..
31:211-221.
2010
-
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes..
31:50-58.
2010
-
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction.
31:573-581.
2010
-
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis.
31:1257-1265.
2010
-
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry..
30:2318-2326.
2009
-
Early in-ospital worsening heart failure predicts adverse outcome in patients.
30:719-719.
2009
-
Echocardiographic predictors of long-term survival in adults with pulmonary hypertension.
30:115-115.
2009
-
Effects of the new vasodilator relaxin for the treatment of patients with acute heart failure and normal to elevated blood pressure: results of a phase 2b study (Pre-RELAX-AHF).
30:424-425.
2009
-
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial..
30:2226-2232.
2009
-
Impact of anemia in patients with pulmonary hypertension.
30:260-260.
2009
-
Impact of incidentally discovered patent foramen ovale and its operative repair on long-term survival.
30:6-6.
2009
-
Improved pulmonary insufficiency with inhaled vasodilator assessed by cardiac magnetic resonance imaging.
30:811-811.
2009
-
Increased symptom-improvement with the novel vasodilator, relaxin, in Acute Heart Failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study.
30:164-164.
2009
-
Novel intravascular defibrillator (InnerPulse PICD): defibrillation thresholds of PICD compared to Medtronic ICD in a canine model.
30:276-276.
2009
-
Patient-reported dyspnea in acute heart failure trials. Use of the Likert and the visual analog scales in the pre-RELAX AHF study.
30:445-446.
2009
-
Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme.
30:876-876.
2009
-
Pulmonary vasodilator challenge predicts survival in patients with various etiologies of pulmonary hypertension.
30:899-900.
2009
-
Racial disparities in survival in patients with pulmonary hypertension.
30:513-513.
2009
-
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis..
30:2213-2219.
2009
-
Time to treatment and vasodilator efficacy in acute heart failure: Results from the Pre-RELAX-AHF study.
30:424-424.
2009
-
Worsening renal function in acute heart failure: change in BP and effects of relaxin.
30:1020-1021.
2009
-
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)..
30:1450-1456.
2009
-
Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials..
30:1245-1253.
2009
-
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes..
30:1195-1202.
2009
-
Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery..
30:995-1004.
2009
-
Whose heart will get broken? Troponin testing and future heart failure..
30:755-756.
2009
-
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes..
30:655-661.
2009
-
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: A risk model from the ACUITY trial.
30:1457-1466.
2009
-
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007..
30:152-161.
2009
-
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure.
30:338-345.
2009
-
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme..
29:3022-3028.
2008
-
Is thrombogenesis related to residual platelet function in ischaemic heart disease?: Reply.
29:3065-3066.
2008
-
Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry..
29:3052-3060.
2008
-
Erythropoietin, haemoglobin, heart failure, and mortality: Reply.
29:2695-2696.
2008
-
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme..
29:2641-2650.
2008
-
Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes..
29:2480-2488.
2008
-
Acute severe hypertension has high morbidity, mortality, and readmission rates: results from the STAT registry.
29:513-513.
2008
-
An RNA aptamer inhibiting factor IXa and its complementary oligonucleotide antidote.
29:328-328.
2008
-
Association between C-reactive protein and generalized anxiety disorder in stable coronary heart disease patients..
29:2212-2217.
2008
-
Cognitive function and anticoagulation control in patients with atrial fibrillation.
29:258-258.
2008
-
Endoscopic vein harvesting is a strong independent predictor of vein graft failure in patients undergoing coronary artery bypass graft surgery.
29:284-285.
2008
-
Has the frequency of bleeding improved over time for patients presenting with an acute coronary syndrome? The GRACE Registry.
29:326-326.
2008
-
Impact of incidentally discovered patent foramen ovale and its repair on perioperative outcomes in 13,260 cardiothoracic surgery patients.
29:124-124.
2008
-
Late recanalization of infarct related artery has no impact on clinical outcomes regardless of ejection fraction: Results from the Occluded Artery Trial (OAT).
29:679-679.
2008
-
Mechanical complications are uncommon in STEMI treated with primary-PCI: insights from APEX-AMI.
29:137-138.
2008
-
Mortality after cardiogenic shock remains high in ST-elevation myocardial infarction treated with primary PCI: insights from APEX AMI.
29:447-447.
2008
-
Prevalence and predictors of dyssynchrony as determined by gated SPECT perfusion imaging in patients with left ventricular dysfunction.
29:5-5.
2008
-
Surgical treatment of anomalous coronary arteries passing between the great vessels in older adults may not improve survival.
29:7-7.
2008
-
Triple combination Ezetimibe/Simvastatin plus extended release Niacin therapy improves ratios of ApoB/ApoA-I containing lipoproteins in hyperlipidemia patients.
29:345-346.
2008
-
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial..
29:1827-1833.
2008
-
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad..
29:1729-1738.
2008
-
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients..
29:1510-1515.
2008
-
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
29:1377-1385.
2008
-
Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative..
29:1103-1109.
2008
-
Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy..
29:871-879.
2008
-
Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients..
29:1011-1018.
2008
-
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb..
29:880-887.
2008
-
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study..
29:748-756.
2008
-
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment..
29:315-323.
2008
-
Reperfusion after primary angioplasty for ST-elevation myocardial infarction: Predictors of success and relationship to clinical outcomes in the APEX-AMI Angiographic Study.
29:1127-1135.
2008
-
Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: We are getting better but we have got a long way to go.
29:609-617.
2008
-
When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'?.
28:2960-2961.
2007
-
Cardiovascular disease on a global scale: defining the path forward for research and practice..
28:2678-2684.
2007
-
A new model for predicting mortality in acute ST elevation myocardial infarction treated with primary PCI: results from the APEX AMI trial.
28:59-59.
2007
-
Adverse outcomes in fibrinolytic-based facilitated PCI: insights from the ASSENT-4 PCI electrocardiographic substudy.
28:59-59.
2007
-
Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes.
28:259-260.
2007
-
Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.
28:516-516.
2007
-
Can we predict non-fatal cardiovascular events in acute coronary syndrome? The Global Registry of Acute Coronary Events.
28:689-689.
2007
-
Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: an analysis using propensity score methods.
28:184-184.
2007
-
Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women..
28:2064-2069.
2007
-
Outcomes for stenting in single and multivessel coronary artery disease using established and novel paclitaxel eluting stent platforms: COSTAR II.
28:577-577.
2007
-
Predictors of angiographic success and relationship to clinical outcomes during primary PCI for ST elevation acute myocardial infarction: insights from APEX-AMI.
28:660-660.
2007
-
Short-term outcomes are at least as good with drug eluting vs. bare metal stents: insights from APEX AMI.
28:9-9.
2007
-
Similar association between age and outcomes in high-risk ACS patients treated with enoxaparin or unfractionated heparin.
28:218-218.
2007
-
The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.
28:187-187.
2007
-
Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab.
28:384-385.
2007
-
Retinal vessel diameter and cardiovascular mortality: pooled data analysis from two older populations..
28:1984-1992.
2007
-
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes..
28:1598-1660.
2007
-
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction..
28:1709-1716.
2007
-
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes..
28:1193-1204.
2007
-
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study..
28:1109-1116.
2007
-
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial..
28:1079-1084.
2007
-
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry..
28:980-988.
2007
-
Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial..
28:685-691.
2007
-
Ruminating on OAT: is the case closed?.
28:531-532.
2007
-
The cost of implantable defibrillators: how the perception of reality depends on perspective.
28:386-387.
2007
-
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials..
28:425-432.
2007
-
The high cost of implantable defibrillators..
28:388-391.
2007
-
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction..
28:415-424.
2007
-
Diabetes mellitus and insulin therapy in infective endocarditis.
28:3-4.
2007
-
Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: Lessons from APEX-AMI.
28:2850-2857.
2007
-
Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial..
27:3027-3032.
2006
-
Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?.
27:2737-2739.
2006
-
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes..
27:2956-2961.
2006
-
Is acute heart failure a highly prevalent orphan disease?.
27:2619-2620.
2006
-
Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study..
27:2516-2523.
2006
-
Glucose, insulin, and acute myocardial infarction: Reply [4].
27:2142-2143.
2006
-
A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study..
27:1530-1538.
2006
-
International variation in invasive care of the elderly with acute coronary syndromes..
27:1558-1564.
2006
-
Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study..
27:1289-1297.
2006
-
Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
27:1447-1458.
2006
-
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial..
27:1198-1206.
2006
-
Persistent and reversible cardiac dysfunction among amateur marathon runners..
27:1079-1084.
2006
-
Aborted myocardial infarction: a new target for reperfusion therapy..
27:901-904.
2006
-
NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy..
27:839-845.
2006
-
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes..
27:527-533.
2006
-
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction..
27:419-426.
2006
-
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts..
27:323-329.
2006
-
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study..
27:330-337.
2006
-
Predictors of mortality and morbidity in patients with chronic heart failure..
27:65-75.
2006
-
Imaging approach to the assessment of cardiomyopathies using delayed enhancement cardiovascular magnetic resonance..
26:2601-2602.
2005
-
Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention..
26:2396-2403.
2005
-
Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes..
26:2106-2113.
2005
-
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry..
26:2114-2119.
2005
-
Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction..
26:1937-1938.
2005
-
Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial..
26:1964-1970.
2005
-
A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy..
26:1726-1733.
2005
-
Simplifying risk stratification in non-ST-segment elevation acute coronary syndromes.
26:431-431.
2005
-
Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies..
26:1461-1474.
2005
-
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial..
26:1506-1512.
2005
-
Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry..
26:1063-1069.
2005
-
The effect of intra-aortic balloon counterpulsation on left ventricular functional recovery early after acute myocardial infarction: a randomized experimental magnetic resonance imaging study..
26:1235-1241.
2005
-
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction..
26:667-674.
2005
-
The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort.
26:421-422.
2005
-
Aorto-cavitary fistulous tract formation in infective endocarditis: Clinical and echocardiographic features of 76 cases and risk factors for mortality.
26:288-297.
2005
-
Assessing risk in FRISC..
26:103-104.
2005
-
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials..
26:128-136.
2005
-
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry..
25:1911-1919.
2004
-
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial..
25:1688-1694.
2004
-
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS..
25:1494-1501.
2004
-
Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging..
25:1419-1427.
2004
-
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes..
25:313-321.
2004
-
Effect of candesartan on New York Heart Association functional class - Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
25:1920-1926.
2004
-
International variation in the use of evidence-based medicines for acute coronary syndromes..
24:2133-2141.
2003
-
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial..
24:1807-1814.
2003
-
Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible?.
24:1613-1615.
2003
-
International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2..
24:1640-1650.
2003
-
From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)..
24:1414-1424.
2003
-
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction..
24:1515-1522.
2003
-
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study..
24:897-908.
2003
-
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?.
24:522-531.
2003
-
Cardiac markers in acute coronary syndromes-refining our knowledge..
24:136-137.
2003
-
Plasma homocysteine levels independently correlate with angiographic extension of coronary artery disease.
24:436-436.
2003
-
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes..
24:172-181.
2003
-
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making..
24:182-189.
2003
-
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes..
23:1538-1545.
2002
-
Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion..
23:1449-1455.
2002
-
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy..
23:1202-1212.
2002
-
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial..
23:1102-1111.
2002
-
Assessment of myocardial viability by cardiovascular magnetic resonance imaging..
23:602-619.
2002
-
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker..
23:239-246.
2002
-
Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction.
23:550-557.
2002
-
Determinants of matrix metalloproteinases plasma concentration and activity in premature coronary atherosclerosis.
23:135-135.
2002
-
Effect of simvastatin on endothelial damage markers and clinical outcomes in acute coronary syndromes.
23:419-419.
2002
-
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA..
22:2253-2261.
2001
-
ESPRIT in context: pharmacology matters!.
22:1965-1967.
2001
-
Baseline characteristics that identify patients at high risk of death following myocardial infarction. Preliminary findings from the ALIVE trial.
22:700-700.
2001
-
Body mass index remains a significant predictor of outcome after percutaneous coronary interventions in the era of IIbIIIa inhibition.
22:524-524.
2001
-
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study..
22:1601-1612.
2001
-
Eptifibatide (Integrilin (R)) in coronary stent implantation: long-term results of the ESPRIT trial.
22:121-121.
2001
-
Genetic variation in human Stromelysin-1 and Gelatinase B genes and acute coronary syndromes in young males.
22:164-164.
2001
-
Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials.
22:385-385.
2001
-
Low heart rate variability (triangular index method) predicts mortality independent of beta-blocker usage, LVEF, and other factors: ALIVE trial early findings.
22:701-701.
2001
-
Pharmacokinetic and pharmacodynamic responses of the novel factor Xa inhibitor DX-9065a: results from the Xa neutralization for atherosclerotic disease understanding (XaNADU) IB trial.
22:664-+.
2001
-
The ALIVE study: heart rate variability prospectively identifies patients at high risk of death after myocardial infarction.
22:696-+.
2001
-
Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial..
21:1967-1978.
2000
-
Lack of progress in cardiogenic shock: lessons from the GUSTO trials..
21:1928-1936.
2000
-
Reperfusion synergism: will it be both sustained and safe?.
21:1913-1916.
2000
-
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators..
21:1750-1758.
2000
-
Inter-regional differences in acute coronary syndrome trials..
21:1397-1399.
2000
-
Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction..
21:1502-1513.
2000
-
National and regional registries: what good are they?.
21:1401-1403.
2000
-
Troponins in pericarditis: implications for diagnosis and management of chest pains patients..
21:798-800.
2000
-
American College of Cardiology/ European Society of Cardiology international study of angiographic data compression phase I. The effects of lossy data compression on recognition of diagnostic features in digital coronary angiography..
21:668-678.
2000
-
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT..
21:371-381.
2000
-
Very early diagnosis and risk stratification of patients admitted with suspected acute myocardial infarction by the combined evaluation of a single serum value of cardiac troponin-T, myoglobin, and creatine kinase MB(mass).
21:382-389.
2000
-
Educational level and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.
21:223-223.
2000
-
Social isolation and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.
21:213-213.
2000
-
The level of platelet inhibition maintained with a GPIIb/IIIa inhibitor following coronary intervention is strongly associated with the risk of a post-procedural MACE: results of the GOLD study.
21:145-145.
2000
-
Use of a near-patient, whole blood, multi-marker strategy (MMS) for evaluation of patients with chest pain: Results of the CHECKMATE study.
21:19-19.
2000
-
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry..
20:1182-1190.
1999
-
Minimal myocardial damage during coronary intervention is associated with impaired outcome..
20:1112-1119.
1999
-
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III.
20:128-135.
1999
-
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries..
20:128-135.
1999
-
Improved outlook for patients with acute myocardial infarction: an interim progress report..
19:1416-1418.
1998
-
Mechanism of protective effects of ACE inhibition on coronary artery disease..
19 Suppl J:J2-J6.
1998
-
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes..
19 Suppl D:D22-D30.
1998
-
International roundtable on Use of GP IIb/IIIa inhibitors in coronary syndromes: State of the art, Davos, Switzerland, 15-16 February 1997: Foreward.
19.
1998
-
The GUSTO trial and the open artery theory..
18 Suppl F:F2-10.
1997
-
Nebulized prostacyclin for pulmonary hypertension: a step in the right direction..
18:1364-1365.
1997
-
Predictors of outcome of reperfusion therapy..
18:728-735.
1997
-
Pragmatic and mechanistic trials..
18:367-370.
1997
-
Selection of reperfusion therapy for individual patients with evolving myocardial infarction.
18:1371-1381.
1997
-
The rationale for thrombolytic therapy..
17 Suppl E:2-8.
1996
-
Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis..
17:978-980.
1996
-
Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial..
17:689-698.
1996
-
Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction..
17:399-406.
1996
-
Erratum: Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial (European Heart Journal (1996) 17 (689-698)).
17:1451.
1996
-
An overview of the results of the EPIC trial..
16 Suppl L:43-49.
1995
-
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor..
16 Suppl L:50-55.
1995
-
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction.
16:1024-1026.
1995
-
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries..
16:1024-1026.
1995
-
Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischaemia..
15:1356-1361.
1994
-
Emerging role of the tissue renin-angiotensin systems in congestive heart failure..
11 Suppl B:65-71.
1990
-
In vitro analysis of jets by Doppler colour flow imaging: the importance of time to maximum jet area..
11:361-367.
1990
-
New interventional technology for the management of multivessel coronary artery disease..
10 Suppl H:52-56.
1989
-
Heart rate and metabolic response to competitive squash in veteran players: identification of risk factors for sudden cardiac death..
10:1029-1035.
1989
-
Vascular and renal prostaglandins as counter-regulatory systems in heart failure..
9 Suppl H:15-19.
1988
-
Spontaneously healing infective endocarditis: An unrecognized phenomenon?.
8:327-330.
1987
-
Guidelines for exercise therapy of the elderly after myocardial infarction..
5 Suppl E:121-123.
1984
-
The value of early out-patient cardiac exercise programmes for the elderly in comparison with other selected age groups..
5 Suppl E:113-115.
1984
-
A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome.
ehv758-ehv758.
-
Imaging approach to the assessment of cardiomyopathies using delayed enhancement cardiovascular magnetic resonance: reply.
26:2602-2602.
-
Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry.
37:161-163.
-
Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry
2018
-
Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial
2018
-
A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials
2017
-
Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin
2017
-
Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF)
2017
-
Diabetes and cardiovascular risk in patients with symptomatic peripheral artery disease
2017
-
INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin
2017
-
Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial
2017
-
Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials
2017
-
Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial
2017
-
The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial
2017
-
The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID
2017
-
Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial
2017
-
Are clinicians following statin intensity recommendations? Insights in 135 U.S community practices in the PALM registry
2016
-
Comparing novel biomarkers associated with heart failure preserved ejection fraction (HFpEF): A matched case-control analysis
2016
-
Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study
2016
-
Mechanisms and impact on cardiac mortality of right ventricular dysfunction in non-ischaemic cardiomyopathy
2016
-
Multinational ethnic variations in self-reported health status in chronic heart failure patients
2016
-
Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation
2016
-
Patient receptiveness to statin therapy is higher when presented with lifetime risk rather than 10-year risk of cardiovascular disease: insights from the PALM registry
2016
-
Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial
2016
-
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF)
2016
-
Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT AF)
2016
-
Plasma amino acid concentrations are independently associated with adverse outcomes in heart failure and preserved ejection fraction: prognostic utility of amino acid profiles in HFpEF
2016
-
Systemic embolization in patients with atrial fibrillation: results from ROCKET AF
2016
-
The EVEREST II REALISM Continued Access Study-1 year outcomes in patients with functional mitral regurgitation reported by baseline New York Heart Association functional class
2016
-
Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart disease - Experiences from the STABILITY biomarker substudy
2015
-
Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial
2015
-
Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial
2015
-
Effect of ivabradine on heart rate variability in patients with stable coronary artery disease
2015
-
Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial
2015
-
External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation
2015
-
Hypotension in patients with acute heart failure: Insights from RELAX-AHF
2015
-
Impact of pulmonary hypertension on mortality in patients treated with nitric oxide for failure to wean following cardiothoracic surgery
2015
-
Improved survival after out-of-hospital cardiac arrest most substantial in younger patients - results from a statewide quality improvement initiative in North Carolina during 2010-2013
2015
-
Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study
2015
-
LDL cholesterol remains an important predictor of coronary heart disease events even in the statin era
2015
-
Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial
2015
-
Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial
2015
-
Off-hours versus regular hours admission and its relation with long-term mortality of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention
2015
-
Outcomes of rivaroxaban versus warfarin in women and men with nonvalvular atrial fibrillation: results from the ROCKET AF trial
2015
-
Rivaroxaban vs. warfarin with concomitant aspirin use in patients with atrial fibrillation: findings from the ROCKET AF trial
2015
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment
2015
-
Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation
2015
-
Survival improved for men but not women, despite increased bystander CPR and first resonder defibrillation for both: results form a statewide quality improvement initiative
2015
-
The EVEREST II REALISM Continued Access study-1 year outcomes in patients with primary mitral regurgitation
2015
-
The evolution of ICD programming practice: What is the relative impact of clinical evidence on clinical practice?
2015
-
Treatment consistency across levels of baseline renal function with rivaroxaban compared with warfarin: insights from ROCKET AF
2015
-
A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score
2014
-
Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial
2014
-
Future risk of coronary heart disease due to uncontrolled hyperlipidemia in early adulthood
2014
-
Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial
2014
-
Impact of early initiation of intravenous prostanoid therapy in patients with congenital heart disease-related pulmonary arterial hypertension
2014
-
Impact of insurance status on survival in pulmonary hypertension
2014
-
Incidence and impact of patent foramen ovale among patients with pulmonary hypertension
2014
-
Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation
2014
-
Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation - Results from ROCKET AF
2014
-
Predictors of and clinical outcomes after internal mammary artery graft failure: insights from the PREVENT-IV trial
2014
-
Relationship between troponin levels and long-term outcomes in medically managed patients with non-ST-segment elevation acute coronary syndromes: insights from the TRILOGY ACS trial
2014
-
The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment
2014
-
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
2014
-
A composite peripheral blood gene expression score has high sensitivity for obstructive coronary artery disease in a non-invasive imaging population and correlates with plaque burden and morphology by
2013
-
A systematic review of outcomes related to hybrid coronary revascularization in patients with multi-vessel coronary artery disease in the drug-eluting stent era
2013
-
ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy
2013
-
Association between type of valve prosthesis and one year mortality in IE: an analysis of 1467 patients from the International collaboration on endocarditis prospective cohort study
2013
-
International variation in management and outcomes in high-risk patients following acute coronary syndromes: results from the APPRAISE-2 trial
2013
-
Mechanical dyssynchrony defined by phase analysis from GSPECT: Does it predict all cause and cardiovascular mortality?
2013
-
Reperfusion arrhythmia bursts predict larger infarct size in STEMI patients undergoing primary percutaneous coronary intervention despite optimal epicardial and microvascular flow
2013
-
Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial
2013
-
Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE
2013
-
Ventricular arrhythmia bursts following primary percutaneous coronary intervention for acute myocardial infarction: correlations with microvascular obstruction and final infarct size using CMR
2013
-
Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial
2012
-
Baseline hemoglobin predicts post-discharge events in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial
2012
-
Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis
2012
-
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia
2012
-
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial
2012
-
Inadequate anticoagulant therapy during end of study transition to open-label vitamin K antagonist therapy: experience in ROCKET AF
2012
-
Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy
2012
-
Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death
2012
-
NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin
2012
-
New insight into mental stress induced myocardial ischemia: prevalence and demographic/clinical characteristics
2012
-
Racial differences in acute aortic dissection: insights from the International Registry of Acute Aortic Dissection
2012
-
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial
2012
-
Unmasked pulmonary venous hypertension during vasodilator challenge predicts poor outcomes with medical therapy
2011
-
Acute renal failure after coronary artery bypass surgery: impact of recovery of renal function on long-term mortality
2010
-
No significant increase in the incidence of infective endocarditis following the cessation of antibiotic prophylaxis for dental procedures
2010
-
Prognostic value of Galectin-3 in chronic heart failure: results from the HF-ACTION Study
2010
-
Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the PREVENT-IV trial
2010
-
A practical, validated model for prediction of risk in chronic heart failure
2006
-
Contraindications to cardiac catheterization in non-ST-elevation acute coronary syndromes: Insights from the CRUSADE national quality improvement initiative
2006
-
Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes
2006
-
Low dose enoxaparin in non-ST segment elevation acute coronary syndrome, followed by antiplatelet therapy alone during subsequent percutaneous coronary intervention
2006
-
Patients with acute ST-elevation myocardial infarction and prehospital delay to presentation > 12 hours: high risk of worse outcomes and selective use of reperfusion therapies. The GRACE registry
2006
-
Racial differences in high-risk patients presenting with NSTE ACS: results from the SYNERGY trial
2006
-
Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial
2006
-
Analysis of all recurrent events is superior to the time-to-first event in assessment of drug therapy to prevent ICD therapies
2005
-
Atrial fibrillation carries similar risks in heart failure irrespective of ejection fraction-results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)
2005
-
Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme
2005
-
Deriving a safety index from the GRACE risk score
2005
-
Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of acute coronary events
2005
-
Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme
2005
-
Female gender is an independent predictor of better outcome in chronic heart failure: results from the CHARM programme
2005
-
International and time trends in the use and characteristics of patients with acute coronary syndromes treated with clopidogrel: the global registry of acute coronary events experience
2005
-
Intravenous unfractionated heparin, patient profile, and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH registry
2005
-
Predictors of quality of life in symptomatic heart failure patients across the left ventricular ejection fraction spectrum
2005
-
The importance of resting wall motion abnormalities for the diagnostic accuracy of a multicomponent stress CMR test
2005
-
Use of insulin sensitizing agents in outpatients with congestive heart failure appears safe, and may have important clinical benefits when compared with sulfonylureas and insulin
2005
-
Women (especially younger women) with chronic heart failure are less adherent to medication: results from the CHARM program
2005
-
"Leading and lagging" hospitals: can processes of care be used to rank hospitals?
2004
-
Continuous ST-segment recovery analysis is significantly more predictive of mortality than serial static analysis after thrombolytic therapy for acute MI
2004
-
Low haemoglobin is associated with more evidence of congestion but less severe systolic dysfunction in patients with chronic heart failure
2004
-
Substantial reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials
2004
-
2704 Understanding time to treatment in acute myocardial infarction: insights from ASSENT 3 plus
2003
-
755 Relation of myocardial scarring to clinical risk factors for sudden death in hypertrophic cardiomyopathy
2003
-
P1022 A prospective registry of patients hospitalized for worsening heart failure: observations from the IMPACT-HF registry
2003
-
P1102 Mechanism of pexelizumabs mortality benefit in acute myocardial infarction patients treated with primary percutaneous coronary intervention
2003
-
P1627 Does infarct size measured by creatine kinase-MB predict clinical outcomes after fibrinolysis and primary percutaneous coronary intervention?
2003
-
P2848 Enoxaparin versus unfractionated heparin with tenecteplase in the elderly: combined ASSENT-3 and ASSENT-3 PLUS results
2003
-
P2856 Cumulative meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions
2003
-
P2865 Treating patients with acute coronary syndromes with aggressive anti-platelet agents in the grace registry: no observed decrease in in-hospital mortality but increased bleeding complications
2003
-
P2870 Elective percutaneous coronary intervention using anti-platelet therapy alone, without unfractionated heparin or other anti-thrombin therapy
2003
-
Cost-effectiveness of valsartan in patients not receiving angiotensin-converting enzyme inhibitors at baseline
2002
-
Effect of tenecteplase versus alteplase on platelets in patients during the first three hours after acute myocardial infarction
2002
-
How does ST-segment resolution one-hour after fibrinolysis for acute myocardial infarction predict final infarct size? Insights from ASSENT 3
2002
-
Predictors of in-hospital mortality in the global registry of acute coronary events (GRACE)
2002
-
TNK with reduced dose unfractionated heparin associated with similar efficacy and less bleeding: results from ASSENT-2 and ASSENT-3
2002
-
Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure
2001
-
Perspectives gained from large-scale thrombolytic comparative trials.
1996
-
Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers.
1995